About Octimet
Octimet is a startup based in Germany.
Octimet Oncology NV develops targeted cancer therapies including OMO-1, a selective oral MET kinase inhibitor, and OMO-2, a dual MET and RAS pathway inhibitor, aimed at treating lung cancer and other oncology indications.
Explore Octimet's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.